NCT03007810View on ClinicalTrials.gov

Safety and Pharmacokinetics of Hemay005 In Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2018

Conditions
Psoriasis
Interventions
DRUG

Hemay005

Subjects will be randomized into 6 cohorts(10mg, 20mg, 40mg, 80mg, 120mg, 180mg) orally single dose

DRUG

Placebos

Subjects will be randomized into 5 cohorts(20mg, 40mg, 80mg, 120mg, 180mg) orally single dose

Trial Locations (1)

Unknown

Peking Union Medical College Hospital, Beijin

All Listed Sponsors
lead

Tianjin Hemay Bio-Tech Co., Ltd

INDUSTRY

NCT03007810 - Safety and Pharmacokinetics of Hemay005 In Healthy Male Subjects | Biotech Hunter | Biotech Hunter